Ractigen wins FDA IND clearance for saRNA candidate
August 03, 2026 | 15:36
Ractigen Therapeutics received US FDA clearance for its Investigational New Drug application for RAG-1C, a first-in-class small activating RNA candidate to treat proliferative vitreoretinopathy.
Mobile Version